超血导致抗精神病药物相关的肥胖和代谢障碍
Shangang Zhao1,2, Qian Lin1, Wei Xiong3
1Touchstone Diabetes Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Science translational medicine
|November 22, 2023
概括
抗精神病药物会增加体重,因为在体重明显增加之前,它会增加瘦素水平. 中和瘦素可以预防肥胖和代谢问题,这表明瘦素抑制是治疗策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 代谢障碍 代谢障碍 代谢障碍
- 神经科学是一个神经科学.
背景情况:
- 抗精神病药物对于精神疾病是有效的,但通常会导致显著的体重增加和糖尿病.
- 在接受抗精神病药物治疗的患者中,在体重增加之前,观察到较高的丁水平 (高丁血症) 早期.
- 抗精神病药物诱导的超血在代谢功能障碍中的作用尚不清楚.
研究的目的:
- 为了研究超血症在抗精神病药物诱导的肥胖和代谢恶化中的因果作用.
- 为了确定抑制瘦素是否可以减轻这些不良影响.
主要方法:
- 利用小鼠模型模仿抗精神病药物诱导的肥胖和胰岛素抵抗.
- 给药了一种勒素中和抗体,以抑制升高的勒素水平.
- 评估体重增加,葡萄糖耐受性,脂肪组织,肝功能和炎症.
主要成果:
- 在小鼠模型中,确认的超血症在体重增加之前.
- 已经证明,高莱普丁血症直接导致肥胖和代谢障碍.
- 瘦素抑制可以防止体重增加,改善葡萄糖耐受性,并保持器官功能.
- 在接受丁抑制治疗的小鼠中减少了局部和全身炎症.
结论:
- 超血是抗精神病药物相关体重增加和代谢下降的关键因素.
- 瘦素抑制成为一种潜在的治疗策略,以抵消这些副作用.
相关概念视频
Obesity
507
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
507
Overview of Lipid Metabolism
1.6K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
1.6K
Regulation of Food Intake
245
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
245
Oral Hypoglycemic Agents: Biguanides and Glitazones
210
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
210
Glucagon-like Receptor Agonists
331
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
331
Hypoglycemia and Glucagon
273
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
273


